FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer
FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.